Publication date: November 2026 Source: The Lancet Diabetes & Endocrinology, Volume 14, Issue 11 Author(s): W Timothy Garvey, Jamy Ard, Lisa Connery, Juan Pablo Frias, Carel W le Roux, Kirsi H Pietiläinen, Maj Dinesen, Berith F Hagen, Louise Larsen, Dan Hesse, David M Kendall
Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. // The Lancet Diabetes & Endocrinology. – URL: https://www.sciencedirect.com/science/article/pii/S2213858726002135?dgcid=rss_sd_all
Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Diabetes & Endocrinology. https://www.sciencedirect.com/science/article/pii/S2213858726002135?dgcid=rss_sd_all
“Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.” The Lancet Diabetes & Endocrinology.
@article{article68398,
title = {Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial},
journal = {The Lancet Diabetes \& Endocrinology},
url = {https://www.sciencedirect.com/science/article/pii/S2213858726002135?dgcid=rss_sd_all}
}
Abstract Background Macrophage polarisation plays a crucial role in sepsis‐associated inflammatory responses; however, the underlying molecular regulatory mechanisms remain to be further explored. Aim This study aimed to explore the...